Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achondroplasia D000130 1 associated lipids
Acinetobacter Infections D000151 4 associated lipids
Acne Vulgaris D000152 35 associated lipids
Acquired Immunodeficiency Syndrome D000163 12 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Agammaglobulinemia D000361 4 associated lipids
Airway Obstruction D000402 13 associated lipids
Amebiasis D000562 2 associated lipids
Anaphylaxis D000707 35 associated lipids
Anaplasmataceae Infections D000711 3 associated lipids
Angina, Unstable D000789 14 associated lipids
Aphasia, Broca D001039 1 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bartonella Infections D001474 3 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Arrieta A et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. 2003 Antimicrob. Agents Chemother. pmid:14506028
Bingen E et al. Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections. 2003 Antimicrob. Agents Chemother. pmid:12821495
Matlow A et al. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. 1998 Antimicrob. Agents Chemother. pmid:9593171
Pettus K et al. In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae. 2015 Antimicrob. Agents Chemother. pmid:25624328
Girard AE et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. 1987 Antimicrob. Agents Chemother. pmid:2830841
Chang HR and Pechère JC In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2837140
Mulet X et al. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. 2009 Antimicrob. Agents Chemother. pmid:19188376
Jacobsson S et al. Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae. 2017 Antimicrob. Agents Chemother. pmid:28893785
Seyama S et al. Amino Acid Substitution in the Major Multidrug Efflux Transporter Protein AcrB Contributes to Low Susceptibility to Azithromycin in Haemophilus influenzae. 2017 Antimicrob. Agents Chemother. pmid:28848006
Caceres SM et al. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. 2014 Antimicrob. Agents Chemother. pmid:25182651
Jacobs MR et al. Study design questions in treatment of children with acute otitis media. 2004 Antimicrob. Agents Chemother. pmid:15241848
Kemp MW et al. Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy. 2014 Antimicrob. Agents Chemother. pmid:25155606
Blandizzi C et al. Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients. 2002 Antimicrob. Agents Chemother. pmid:11959610
Hunt Gerardo S et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. 1996 Antimicrob. Agents Chemother. pmid:8891154
Zheng S et al. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. 2014 Antimicrob. Agents Chemother. pmid:25155592
Steele-Moore L et al. In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. 1999 Antimicrob. Agents Chemother. pmid:10383373
Descours G et al. Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila. 2017 Antimicrob. Agents Chemother. pmid:28069647
Engel JN Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. 1992 Antimicrob. Agents Chemother. pmid:1280057
Saini H et al. Azithromycin-Ciprofloxacin-Impregnated Urinary Catheters Avert Bacterial Colonization, Biofilm Formation, and Inflammation in a Murine Model of Foreign-Body-Associated Urinary Tract Infections Caused by Pseudomonas aeruginosa. 2017 Antimicrob. Agents Chemother. pmid:28031194
Girgis NI et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. 1999 Antimicrob. Agents Chemother. pmid:10348767
Starner TD et al. Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. 2008 Antimicrob. Agents Chemother. pmid:17954687
Mukherjee P et al. Emergence of high-level azithromycin resistance in Campylobacter jejuni isolates from pediatric diarrhea patients in Kolkata, India. 2014 Antimicrob. Agents Chemother. pmid:24777098
Achard A et al. Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene. 2008 Antimicrob. Agents Chemother. pmid:18519724
Zasowski E et al. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. 2014 Antimicrob. Agents Chemother. pmid:24752270
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Wong MH et al. Emergence of clinical Salmonella enterica serovar Typhimurium isolates with concurrent resistance to ciprofloxacin, ceftriaxone, and azithromycin. 2014 Antimicrob. Agents Chemother. pmid:24752251
Yoshioka D et al. Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. 2016 Antimicrob. Agents Chemother. pmid:27480866
Jeong BH et al. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. 2016 Antimicrob. Agents Chemother. pmid:27480854
Clark CL et al. Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. 2007 Antimicrob. Agents Chemother. pmid:17876003
Klemens SP and Cynamon MH Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. 1994 Antimicrob. Agents Chemother. pmid:7986001
Andersen SL et al. Efficacy of azithromycin as a causal prophylactic agent against murine malaria. 1994 Antimicrob. Agents Chemother. pmid:7986022
Visalli MA et al. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. 1997 Antimicrob. Agents Chemother. pmid:9303375
Ednie LM et al. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). 1997 Antimicrob. Agents Chemother. pmid:9303406
Mandell GL and Coleman EJ Activities of antimicrobial agents against intracellular pneumococci. 2000 Antimicrob. Agents Chemother. pmid:10952618
Frank MO et al. In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes. 1992 Antimicrob. Agents Chemother. pmid:1336337
O'Reilly T et al. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. 1992 Antimicrob. Agents Chemother. pmid:1336342
Heifets L et al. Mycobacterium avium strains resistant to clarithromycin and azithromycin. 1993 Antimicrob. Agents Chemother. pmid:8031351
Wolinsky E Mycobacterium avium strains resistant to clarithromycin and azithromycin. 1994 Antimicrob. Agents Chemother. pmid:8031406
Bermudez LE and Young LS Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. 1988 Antimicrob. Agents Chemother. pmid:2847644
Salman S et al. Pharmacokinetics of Transfer of Azithromycin into the Breast Milk of African Mothers. 2015 Antimicrob. Agents Chemother. pmid:26711756
Meyer AP et al. Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. 1993 Antimicrob. Agents Chemother. pmid:8285612
Bergman M et al. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. 2006 Antimicrob. Agents Chemother. pmid:16940064
Barry AL et al. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. 1988 Antimicrob. Agents Chemother. pmid:2840016
Araujo FG et al. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2840017
Yamaguchi H et al. Chlamydia pneumoniae resists antibiotics in lymphocytes. 2003 Antimicrob. Agents Chemother. pmid:12760877
Kutlin A et al. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. 2002 Antimicrob. Agents Chemother. pmid:11796350
Jacks SS et al. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. 2003 Antimicrob. Agents Chemother. pmid:12709351
Roord JJ et al. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. 1996 Antimicrob. Agents Chemother. pmid:9124837
Gödeke J et al. Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa. 2013 Antimicrob. Agents Chemother. pmid:23318806
Patel KB et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891147